ENOB
Enochian Biosciences, Inc.
Set alert
- Open
- 0.73
- Prev close
- 0.7125
- Mkt cap
- 33.76M
- Vol
- 87.29K
- Avg vol
- 236.52K
- EPS
- -2.25
- P/E
- -0.34
- Div yield
- 0.00%
More statistics
- Low
- 0.70
- High
- 0.745
- Forward P/E
- 0.00
- Beta
- 0.92
- Short ratio
- 3.55
- Inst. own
- 6.55%
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 12, 2023
- 50-d avg
- 0.8193
- 200-d avg
- 1.24
- 1y target
- 0.00
Key statistics
- Market cap
- 33.76M
- Enterprise value
- 33.73M
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.46
- EPS (TTM)
- -2.25
- Beta
- 0.92
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -6.26M
- Total cash
- 2.95M
- Total debt
- 7.54M
- Return on equity
- -93.88%
- Shares outstanding
- 63.70M
- Short % of float
- 3.89%
- 50-day average
- 0.8193
- 200-day average
- 1.24
Analyst view
Consensus: none
Next earnings
May 12, 2023
Expected May 12, 2023. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 12, 2023 | Mar 1, 2023 | 0.00 | — | — | — |
| May 13, 2022 | Mar 1, 2022 | 0.00 | — | — | — |
| Feb 14, 2022 | Dec 1, 2021 | 0.00 | — | — | — |
| May 17, 2021 | Mar 1, 2021 | 0.00 | — | — | — |
| May 11, 2020 | Mar 1, 2020 | 0.00 | — | — | — |
| Nov 13, 2019 | Sep 1, 2019 | 0.00 | — | — | — |
About Enochian Biosciences, Inc.
Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer. The company's product pipeline includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a gene therapy curative treatment for HBV. It develops ENOB-DC-11, an allogeneic dendritic cell therapeutic vaccine for solid tumors; ENOB-DC-12-XX, allogeneic dendritic cell therapeutic vaccine for other solid tumors; and ENOB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. Enochian Biosciences, Inc. has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was incorporated in 2017 and is headquartered in Los Angeles, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- enochianbio.com
News
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
- 3 Doomed Biotech Stocks Destined for Disaster
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- Stocks That Hit 52-Week Lows On Tuesday
- ENOB FINAL DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Enochian BioSciences, Inc. Investors to Secure Counsel Before Important September 26 Deadline in Securities Class Action – ENOB
- ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Enochian BioSciences, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – ENOB
- Stocks That Hit 52-Week Lows On Tuesday
- Stocks That Hit 52-Week Lows On Friday
- Stocks That Hit 52-Week Lows On Thursday
- Stocks That Hit 52-Week Lows On Wednesday
Your note
Sign in to keep a note on ENOB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GRONFELDT-SORENSEN HENRIK | Director | Purchase | Jan 9, 2019 | 0 |
| GUMRUKCU SERHAT | Beneficial Owner of more than 10% of a Class of Security | Sale | May 17, 2022 | 16,985,800 |
| LEIRE ERIC JEAN MARIE | Chief Executive Officer | Purchase | May 23, 2018 | 73,246 |
| PUCHE LUISA | Chief Financial Officer | Stock Award(Grant) | Dec 15, 2021 | 16,266 |
| SANDLER CARL FOREST JR | Director and Beneficial Owner of more than 10% of a Class of Security | Sale | Mar 21, 2022 | 8,418,190 |
| SINDLEV RENE | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Jun 25, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 2.11% | 1,231,984 | 652.95K | Mar 30, 2023 |
| Vanguard Group, Inc. (The) | 0.55% | 322,276 | 170.81K | Mar 30, 2023 |
| Geode Capital Management, LLC | 0.55% | 318,855 | 168.99K | Mar 30, 2023 |
| State Street Corporation | 0.53% | 307,408 | 162.93K | Mar 30, 2023 |
| Northern Trust Corporation | 0.28% | 163,553 | 86.68K | Mar 30, 2023 |
| Nuveen Asset Management, LLC | 0.21% | 121,513 | 64.40K | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.07% | 416,683 | 220.84K | Dec 30, 2022 |
| iShares Russell 2000 ETF | 0.90% | 350,383 | 185.70K | Feb 27, 2023 |
| Vanguard Extended Market Index Fund | 0.57% | 222,701 | 118.03K | Dec 30, 2022 |
| iShares Russell 2000 Value ETF | 0.52% | 202,518 | 107.33K | Feb 27, 2023 |
| Fidelity Small Cap Index Fund | 0.37% | 145,286 | 77.00K | Jan 30, 2023 |
| TIAA-CREF Funds-Equity Index Fund | 0.24% | 93,458 | 49.53K | Jan 30, 2023 |